Norge -
norsk -
Statens legemiddelverk
covexin 8 vet
zoetis animal health aps - clostridium perfringens, type a, alfa toksoid / clostridium perfringens, type b/ c, beta toksoid / clostridium perfringens, type d, epsilon toksoid / clostridium chauvoei, inaktivert / clostridium novyi, inaktivert / clostridium septikum, inaktivert / clostridium tetani, inaktivert / clostridium sordellii, toksoid / clostridium haemolyticum, inaktivert - injeksjonsvæske, suspensjon
Norge -
norsk -
Statens legemiddelverk
tribovax vet
intervet international bv - 5831 an - clostridium perfringens, type a, alfa toksoid / clostridium perfringens, type b/ c, beta toksoid / clostridium perfringens, type d, epsilon toksoid / clostridium chauvoei, inaktivert / clostridium novyi, inaktivert / clostridium septikum, inaktivert / clostridium tetani, inaktivert / clostridium sordellii, toksoid / clostridium haemolyticum, inaktivert - injeksjonsvæske, suspensjon
Norge -
norsk -
Statens legemiddelverk
covexin 10 vet -
zoetis finland oy - clostridium perfringens type a toksoid / clostridium perfringens type b & c beta toksoid / clostridium perfringens type d epsilon toksoid / clostridium chauvoei / clostridium novyi toksoid / clostridium septikum toksoid / clostridium tetani toksoid / clostridium sordellii / clostridium haemolyticum toksoid - injeksjonsvæske, suspensjon
Den europeiske union -
norsk -
EMA (European Medicines Agency)
regkirona
celltrion healthcare hungary kft. - regdanvimab - covid-19 virus infection - immune sera og immunglobuliner, - regdanvimab is indicated for the treatment of adults with coronavirus disease 2019 (covid-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.
Den europeiske union -
norsk -
EMA (European Medicines Agency)
xevudy
glaxosmithkline trading services limited - sotrovimab - covid-19 virus infection - immune sera og immunglobuliner, - xevudy is indicated for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (covid-19) who do not require oxygen supplementation and who are at increased risk of progressing to severe covid-19.